NASDAQ:ECYT Endocyte (ECYT) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free ECYT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$23.99▼$23.9950-Day Range N/A52-Week Range$2.81▼$24.00VolumeN/AAverage Volume2.12 million shsMarket Capitalization$1.97 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Endocyte alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Endocyte Stock (NASDAQ:ECYT)Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.Read More Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" ECYT Stock News HeadlinesFebruary 16, 2024 | investing.comTelix Pharmaceuticals Ltd (TLX)January 3, 2024 | fool.com.au'The most exciting company in Australia': The ASX stock up 179% in 6 monthsApril 23, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…May 17, 2023 | thestreet.comThe Endocyte Bear Thesis: Why March Will be a Bad MonthJanuary 5, 2023 | thestreet.comWhy Endocyte (ECYT) Stock Is Plummeting in After-Hours Trading TodaySeptember 20, 2022 | finance.yahoo.comGlobal Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo FinanceJune 6, 2022 | globenewswire.comPurdue University impacting lives: successfully delivering innovations to the public - GlobeNewswireMay 23, 2022 | globenewswire.comGlobal Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - GlobeNewswireApril 23, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…May 20, 2022 | benzinga.comCortexyme Appoints Dr. Philip Low to Its Board of Directors - Benzinga - BenzingaMay 20, 2022 | streetinsider.comCortexyme (CRTX) Appoints Philip Low to Its Board - StreetInsider.comMay 3, 2022 | nasdaq.comNovartis Is Looking for Deals. Are These 3 Biotechs on Its List? - NasdaqApril 25, 2022 | seekingalpha.comClovis: Shifting Toward Nuclear Medicine - Seeking AlphaApril 14, 2022 | globenewswire.comGlobal Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Research Inc - GlobeNewswireJanuary 31, 2022 | globenewswire.comNon-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight - GlobeNewswireJanuary 27, 2022 | finance.yahoo.comGlobal Oncology Radiopharmaceuticals Market to Surpass US$ 5,206.8 Million by 2028, Says Coherent Market Insights (CMI) - Yahoo FinanceDecember 19, 2021 | proactiveinvestors.com.auRadiopharm Theranostics enhances management team skillset with three key appointments - Proactive Investors AustraliaNovember 2, 2021 | finance.yahoo.comFusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer - Yahoo FinanceNovember 2, 2021 | streetinsider.comFusion Pharmaceuticals Inc. (FUSN) Appoints Christopher Leamon as Chief Scientific Officer - StreetInsider.comSeptember 20, 2021 | streetinsider.comMirati Therapeutics (MRTX) Appoints David Meek as CEO - StreetInsider.comAugust 16, 2021 | afr.comTelix Pharma is on the cusp of first US FDA approval - The Australian Financial ReviewSee More Headlines Receive ECYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2018Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ECYT CUSIP29269A10 CIK1235007 Webwww.endocyte.com Phone765-463-7175FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,060,000.00 Net Margins-32,296.09% Pretax MarginN/A Return on Equity-21.19% Return on Assets-20.55% Debt Debt-to-Equity RatioN/A Current Ratio45.80 Quick Ratio45.80 Sales & Book Value Annual Sales$70,000.00 Price / Sales28,133.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.99 per share Price / Book12.06Miscellaneous Outstanding Shares82,090,000Free FloatN/AMarket Cap$1.97 billion OptionableOptionable Beta-0.01 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Michael A. Sherman (Age 52)CEO, Pres & Director Mr. Michael T. Andriole (Age 45)Chief Financial Officer Dr. Alison A. Armour (Age 54)Chief Medical Officer Dr. Christopher P. Leamon (Age 52)VP of R&D Dr. Philip S. Low (Age 70)Co-Founder, Chief Science Officer & Director Key CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNCorcept TherapeuticsNASDAQ:CORTPacira BioSciencesNASDAQ:PCRXPerrigoNYSE:PRGOJazz PharmaceuticalsNASDAQ:JAZZView All Competitors ECYT Stock Analysis - Frequently Asked Questions How were Endocyte's earnings last quarter? Endocyte, Inc. (NASDAQ:ECYT) posted its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.02 million. Endocyte had a negative trailing twelve-month return on equity of 21.19% and a negative net margin of 32,296.09%. What other stocks do shareholders of Endocyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endocyte investors own include Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Celldex Therapeutics (CLDX), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), Achaogen (AKAO), Bausch Health Companies (BHC) and Inovio Pharmaceuticals (INO). This page (NASDAQ:ECYT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endocyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
